The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01004835

Acronym

MAPS

Enrollment

Registered

2009-10-30

Start date

2009-01-31

Completion date

2015-05-31

Last updated

2015-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Disease

Keywords

migraine

Brief summary

The objective of this study is to obtain blood or saliva samples to define genes for migraine and pain diseases.

Detailed description

It is estimated that over one-third of the world's population suffers from persistent or recurrent pain. Migraine is highly heritable and the majority of juveniles who suffer from the disorder have a mother or father who also have the disease. The blood or saliva samples will go through DNA analysis and be sequenced for candidate genes or subjected to whole-genome sequencing. By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.

Interventions

None listed

Study design

Observational model

FAMILY_BASED

Eligibility

Sex/Gender

ALL

Age

10 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Family members (genetic duo or trio), consisting of an adolescent 10 to 18 years of age and at least one of their biologic parents willing to be participate in trial 2. Adolescent and at least 1 biologic parent with Migraine diagnosis confirmed by Dr. Christy Jackson 3. Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented 4. Able to understand and grant informed consent

Exclusion criteria

1. Patient has been previously enrolled in the MAP GeneBank at Scripps Clinic Registry 2. Has a significant chronic medical condition (i.e.chronic meningitis or a secondary origin/cause of headache) which, in the investigator's option, may interfere with the patient's optimal participation in the study 3. Treatment with any investigational agents or devices within 30 days preceding enrollment in the study 4. Has undergone ECT within 90 days preceding enrollment in the study

Design outcomes

Primary

Measure	Time frame	Description
Gene identification	end of study	By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.

Countries

United States

Outcome results